Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Thermo Fisher, Cellectis Enter TAL Nucleases Licensing Agreement

Published: Thursday, June 05, 2014
Last Updated: Thursday, June 05, 2014
Bookmark and Share
Cellectis and Thermo Fisher Scientific announced that they have entered into a series of agreements covering the uses of TAL nucleases under the brand name TALEN™.

Pursuant to these agreements, Thermo Fisher is granted a worldwide license under Cellectis’ rights to the TAL nucleases outside the therapeutic field, with exclusive rights to grant sublicenses in research and development, bioproduction and certain applied markets. Thermo Fisher currently markets TALEN™ for these applications under its Life Technologies brand. 

Cellectis is granted a worldwide license under Thermo Fisher’s rights to TAL nucleases in the research and development field for internal and collaborative research, for commercialization of TAL gene editing for Cellectis bioresearch’s products and services, and in the plant biotechnology field for Cellectis plant sciences’ in-house and collaborative research and development. Finally, Cellectis is granted a worldwide license for therapeutic research and development, including rights to grant sublicenses for therapeutic uses in the fields of T cells and Natural Killer cells. 

Dr. André Choulika, Chairman and Chief Executive Officer of Cellectis stated: “We are very pleased to enter into these agreements that strengthen Cellectis’ position in the uses of TALEN™ gene editing in Cellectis’ core businesses, and solidifies our position as a leader in the field of engineered CART Chimeric Antigen Receptors therapeutics. TALEN™ is the state-ofthe- art for gene editing and provides exceptional precision, safety, efficacy and ease of use. TAL nucleases have many applications in genome engineering and their efficacy and specificity make them the world’s best gene editing technology for therapeutic applications. Cellectis founded the field of gene editing 14 years ago and is now primarily focused on adoptive immunotherapy using TALEN™-engineered T cells combined with (CARs).” 

“The agreements between Thermo Fisher and Cellectis create a powerful intellectual property portfolio comprised not only of the foundational work conducted at the University of Minnesota and Martin-Luther-Universitat Halle-Wittenberg, but also additional intellectual property controlled by each party,” said Helge Bastian, general manager and vice president of synthetic biology at Thermo Fisher Scientific. “The ability of TAL effectors to bind to DNA with unprecedented precision and reliability makes this technology invaluable to researchers looking to edit genomes and control gene activity. The current alliance clarifies the path for the use of TALEN™ gene editing in research and applied markets, and represents a major milestone in Thermo Fisher’s strategy to build a comprehensive gene editing technology platform.” 

Commercial terms of the agreements were not disclosed. 

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Extends Collaboration with University of Birmingham
New Phenome Centre Birmingham, UK to use Thermo Scientific mass spectrometry instruments to advance metabolic phenotyping and metabolomics studies.
Tuesday, May 24, 2016
Transcriptome Profiling Grants Launched
Request for proposal aims to identify promising research projects involving precious samples.
Monday, October 20, 2014
Thermo Fisher Scientific, GSK and Pfizer Collaboration
Thermo Fisher Scientific announces agreement with GlaxoSmithKline and Pfizer to develop oncology companion diagnostics using Next-Generation Sequencing (NGS.)
Thursday, September 25, 2014
Thermo Fisher Scientific and Newman-Lakka Institute to Collaborate
The collaboration will research diagnostic approaches for personalized cancer treatment.
Tuesday, June 25, 2013
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Rare Immunodeficiency Yields Unexpected Insights
Scientists uncover previously unknown gene mutation revealing the role of a key molecule involved in immune cell development.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Precision Medicine Guiding Cancer Patients’ Chemotherapy Decision
New study finds doctors use genetic test to measure breast cancer recurrence risk, make tailored treatment recommendations.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos